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Summary Sister chromatid exchange (SCE) induction by two radiosensitizing platinum compounds (cis-
dichloro-bis isopropylamine trans dihydroxy platinum IV (CHIP) and cis-platinum metronidazole2 C12
(FLAP)) was studied in CHO cells in vitro. Both drugs induced SCE in a dose dependent manner. CHIP was
a much more potent inducer of SCE than FLAP and produced almost 4 times as many SCE as FLAP at
equimolar concentrations and twice as many at equitoxic dosage. Induction of SCE by a component of the
FLAP molecule-metronidazole-was also examined. It did not cause any increase of SCE frequency over the
control level when applied at 10 times the highest concentration of FLAP which was used.
Sister chromatid exchange (SCE) formation has
been proposed as a sensitive and simple method for
detecting the mutagenicity of chemical agents (Latt
et al., 1981, Perry, 1980; Perry & Evans, 1975;
Solomon & Bobrow, 1975; White & Hesketh, 1980).
The mode of action of various platinum
coordination compounds has been extensively
studied since their discovery by Rosenberg (for
review see Roberts & Thomson, 1979). Some of the
compounds have been reported to induce
chromosomal aberrations (Van den Berg &
Roberts, 1975; Szumiel & Nias, 1976; Meyene &
Lockhart, 1978; Nias et al., 1979; Bocian et al.,
1983). A positive dose-response relationship for
SCE induction by cis-platinum II diamine
dichloride has also been found (Turnbull et al.,
1979).
In this paper we present the results of studies on
SCE induction by two other platinum complexes;
cis-dichloro-bis isopropylamine trans dihydroxy
platinum (IV) (CHIP) and cis-platinum metro-
nidazole2 Cl2 (FLAP) in CHO cells. CHIP was
found in our previous studies (Nias et al., 1979;
Bocian et al., 1983) to act in a similar way to the
bifunctional alkylating agents with respect to the
production of classic structural chromosomal
aberrations. FLAP is a new platinum coordination
complex which has been shown to be an effective
radiosensitizer toward hypoxic cells in vitro (Bales
et al., 1982) and its mode of action is now being
studied in vivo.
Materials and methods
Cells
Experiments were carried out on an aneuploid line
of CHO cells with 23 chromosomes (Clone 10).
Cells were grown in monolayer culture in HEPES
buffered Minimal Essential Medium (MEM)
supplemented with 15% calf serum, non essential
amino acids and L-glutamine. No antibiotics were
used. (For details see Bocian et al., 1983).
Drug treatment
Stock solutions of CHIP (supplied by Johnson
Matthey Ltd.) and Metronidazole (Sigma) were
prepared in physiological saline. FLAP (supplied by
May and Baker Ltd) was dissolved in propylene
glycol with warming to 700C for 5min. Both
solutions were kept in the dark and freshly
prepared before each experiment. Experiments were
designed according to the protocol suggested by the
GENE-TOX Work Group on Sister Chromatid
Exchanges (Latt et al., 1981). Asynchronous
exponential CHO cell cultures 13-14h after plating
4 x 105 cells per T75 flask were exposed to the
drugs for 1 h at 370C. The medium containing drug
was then removed and replaced by fresh medium
containing 5-bromo-deoxyuridine (BUdR) at a final
concentration of 10pgml1.
Chromosome preparations
Cultures were grown in the presence of BUdR for
the period of two cell cycles (i.e. for 26-30h) in
darkness. Two hours before mitotic collection,
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colcemid (Ciba) at a final concentration of
0.5pgml-P was added to the cultures. To allow for
drug-induced mitotic delay 3 sampling times were
used and mitotic cells were shaken off at 26, 28 and
30h after drug treatment. Chromosome
preparations were made according to the routine
method; cells were treated with 0.075M KCI for
5min and fixed with methanol:glacial acetic acid
(3:1).
SCE staining
A modification of the technique of Perry & Wolff
(1974) was used for SCE visualization. One day old
preparations were stained with 50pgml-1 Hoechst
33258 in PBS for 10min. Then, slides mounted in
2 x SSC buffer warmed up to 37°C were exposed to
UV light (Mineralight Lamp Model UVSL-58) for
1 h. Slides were rinsed well with H20, dried and
subsequently stained with Giemsa stain for 3min.
The stain was prepared from 0.1% Eosin and 0.1%
Azur II stains in 0.06M PBS, pH 6.8.
Results
The frequency of SCEs and the percentage of cells
at the first and second mitoses were estimated for 3
sampling times; 26, 28 and 30h after treatment with
the drug. Data presented in Table I show that the
frequencies of SCE induced by CHIP and FLAP
were similar at each sampling time, independently
of the number of cells which reached the second
mitosis after treatment. Differences between 26 and
30h are statistically insignificant (P=0.3 and
Table I The frequency of SCE and the percentage of
cells at the second mitosis at three sampling times after
treatment with CHIP and FLAP
Time after treatment
(h)
Dose Endpoint
Treatment mM estimated 26 28 30
CHIP 0.12 SCE/cell* 36.22 36.06 34.08
+s.e. 1.01 1.37 1.47
Cells in 2nd 42.96 84.50 94.76
mitosis, % 3.05 1.95 1.69
+s.e.
FLAP 0.50 SCE/cell 11.39 11.83 12.25
+s.e. 0.18 0.35 0.29
Cells in 2nd 54.57 81.25 92.76
mitosis, % 3.01 3.08 1.45
+s.e.
*50 metaphases were scored for SCE at each sampling
time.
P>0.02, for CHIP and FLAP data respectively).
This allowed us to pool together the data obtained
for these sampling times. Thus, the frequency of
SCE estimated for the given concentration of the
drug is the mean value calculated from the
frequencies found for three sampling times, i.e. 26,
28 and 30h after treatment.
The frequency of SCE as a function of the
concentration of CHIP and FLAP is shown in
Figures 1 and 2, respectively. Both drugs caused a
dose-dependent increase in the incidence of SCEs.
The highest dose of CHIP (50pgml-P=0.12mM)
produced a more than 5-fold increase in the
number of SCE (with the range 24-57 SCE cell) as
compared with the control.
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Figure 1 The frequency of SCEs per cell as a function
of CHIP concentration. Points represent the mean
value from 150 metaphases scored (s.e. indicated
wherever greater than the point plotted).
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Figure 2 The frequency of SCEs per cell as a function
of FLAP concentration. Points represent the mean
value from - 150 metaphases scored (s.e. indicated
wherever greater than the point plotted).SCE INDUCED BY PLATINUM RADIOSENSITISERS
The slope of the dose-response curve obtained for
FLAP was very low; the increase of the number of
SCEs per cell (with the range 8-22) was 1.8 fold at
the highest dose (425ygml-1=0.7mM).
CHIP appeared to be a much more potent
inducer of SCEs than FLAP and produced almost
4 times more SCEs than FLAP at an equimolar
concentration (0.12mM). If equitoxic doses are
compared (0.08mM CHIP and 0.7mM FLAP,
Bales et al., 1982) there are still twice as many
SCEs after CHIP as after FLAP.
To learn more about the mechanism of action of
FLAP, the SCE-induction by its component-
metronidazole "Flagyl" was studied. The
experimental protocol was the same as that applied
for FLAP and CHIP. Two concentrations were
used, 0.39mM and 5mM. The lower dose
corresponded to the highest dose of FLAP
(0.7mM) with respect to the molecular equivalent
of the metronidazole content. The higher dose was
approximately 10 times higher to ensure that SCE
would be found if induced by metronidazole alone.
FLAP was dissolved in propylene glycol which
itself is toxic for the cells (at the highest
concentration of 5% the surviving fraction was
0.8). Therefore the incidence of SCEs in the cells
treated with propylene glycol alone was also
estimated. Results of these determinations are
presented in Table II. Neither propylene glycol nor
metronidazole caused an increase in the frequency
of SCEs over the control level (with the range 3-14
SCE/cell).
Table II The influence of metronidazole and propylene
glycol on the frequency of SCE in CHO cells at 28h after
treatment
Number
ofanalysed SCE/cell
Treatment Dose mitoses +s.e.
Control 150 7.80+0.25
Propylene glycol 5% v/v 100 7.96+0.24
Metronidazole 0.39mM 80 8.56+0.16
5.00mM 100 8.26+0.18
Figure 3 shows the dose-response relationship for
the percentage of cells which had only reached first
mitosis and the concentration of FLAP at the 3
sampling times which were used for the estimation
of the incidence of SCEs. From this graph it is
evident that there is a drug-induced dose-dependent
mitotic delay (or prolongation of the cell cycle) in
CHO cells. We did not observe such an effect in the
cells treated with CHIP up to the dose of 0.07mM.
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Figure 3 The relationship between the percentage of
cells at first mitosis and the concentration of FLAP at
3 sampling times after treatment: 26h (O), 28h (a),
30h (a). 200-400 metaphases were counted for each
point (s.e. indicated wherever greater than the point
plotted).
Only the highest dose (0.12mM) induced mitotic
delay (for the data see Table I).
Discussion
Agents capable of crosslinking DNA are among the
most potent in inducing SCE formation (see for
example: Wolff, 1977; Latt et al., 1980; Perry,
1980). The toxicity of antitumour platinum
complexes is thought to be related to their ability to
cause inter- or intrastrand cross-links (Roberts &
Thomson, 1979; Zwelling & Kohn, 1980). In fact,
cis-platinum (II) diamine chloride (neoplatin), one
of the most potent antitumour agents, was
demonstrated to be very active in inducing SCE in
V79 cells (Turnbull et at., 1979). Thus when
undertaking our studies of the formation of SCE by
two other pt-complexes, CHIP and FLAP, we
expected to find them to be active in producing
SCE in CHO cells. Indeed, CHIP appeared to be a
potent inducer of SCE. This was compatible with
our previous studies in which CHIP was shown to
be clastogenic and to act in this respect in a similar
way to the bifunctional alkylating agents (Nias et
al., 1979; Bocian et al., 1983). However, FLAP
induced almost 4 times fewer SCE than CHIP at
equimolar concentration.
On the other hand, FLAP has been shown to be
only one tenth as toxic as CHIP, in terms of
clonogenic survival of CHO cells (Bales et al.,
1982). Nevertheless, even at the highest dose
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applied (0.7mM) which induced a significant
depression of the mitotic index, a long mitotic delay
and survival reduction to -0.03, the frequency of
SCE was still only half that found after treatment
with CHIP at an equitoxic concentration of
0.08mM. At the concentration of FLAP (50gm)
that produced an enhancement ratio of 2.4 in
hypoxic cell radiosensitivity the SCE incidence
remained at the control level. In contrast, at the
CHIP concentration (70gm) that produced an
enhancement ratio of only 1.5 the SCE incidence
was elevated nearly 5-fold.
A component of the FLAP molecule-
metronidazole-did not produce an increase of
SCE over the control level either at a concentration
equimolar to FLAP in respect to this drug's
content in FLAP or over 10 times higher. Our
findings are compatible with those reported earlier
by Prosser & Hesketh (1980). Thus, it seems that
the FLAP molecule as a whole is responsible for
SCE formation and that the platinum component is
important in this respect.
The frequency of SCE appeared to be unaffected
by the number of cells which entered the second
mitosis after treatment with a particular dose of
CHIP or FLAP. Even when as many as 50% of
cells had not reached the second division after drug
treatment the frequency was the same as when
nearly all the cells reached the second mitosis at the
later shake off time (for the same drug dose). This
may suggest that the two phenomena, mitotic delay
and SCE formation, are not mutually related. This
is advantageous from the point of view of the
practical use of SCE analysis for detecting the
mutagenicity ofchemical agents.
There is evidence that the frequency of mutations
induced by a toxic agent can be reduced if cells are
allowed to remain in conditions where potentially
lethal damage (PLD) can be repaired (e.g. holding
in plateau phase or at suboptimal temperatures)
(Rao & Hopwood, 1982). Mitotic delay induced by
FLAP may act in a similar way to allow PLD
repair to take place. This could account for the
lower toxicity of FLAP at equimolar doses and
may be one of the reasons why SCE are lower after
FLAP treatment than after CHIP treatment. On
the other hand the data in Table I show that there
are no fewer SCE in cells which had less time for
repair (26h samples) than those which had more
(30h samples).
It is important to compare the mutagenicity of
agents used in the treatment of cancer. Hall et al.
(1982) used 10T1 mouse fibroblasts to compare the
incidence of oncogenic transformation produced by
a range ofcytotoxic agents. They found a very high
incidence with Neoplatin. X-rays had a smaller
effect as did the hypoxic cell radiosensitizing agent
misonidazole which is similar to metronidazole.
Clearly the beneficial effects of sensitizing agents
must be balanced against such detrimental effects.
Although the SCE assay of mutagenicity cannot be
equated to the oncogenic transformation assay, the
evidence suggests that although platinum
compounds are more mutagenic than
nitroimidazole radiosensitizers the FLAP
compound is less mutagenic than might be expected
from its platinum content.
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